期刊文献+

三氧化二砷诱导K_(562)细胞凋亡的初步研究 被引量:4

Apoptosis of K_( 562) Cell Line Induced by Arsenic Trioxide
下载PDF
导出
摘要 目的:探讨三氧化二砷(As2O3) 治疗慢性粒细胞性白血病(CML) 的机制。方法:以CML细胞系K562 为模型,通过细胞增殖、活力检测、形态学观察、肿瘤集落形成的琼脂糖凝胶电泳等检验。结果:经≥2.5μmol/LAs2O3 处理的K562 细胞可出现增殖受抑和凋亡的形态学改变及DNA片段化。结论:As2O3 能有效地诱导K562 细胞凋亡。 To explore the mechanisms of arsenic trioxide(As 2O 3) in treatment of chronic myelocytic leukemia(CML), K 562 cell line was used as an in vitro model. The effect of As 2O 3 on K 562 cells was observed by cell proliferation, cell viability, cell morphology,tumor colony formation and agarose gel electrophoresis assay. The results showed that As 2O 3 at a concentration greats or equal 2.5μmol/L could inhibit the cell proliferation and induce the apoptotic morphology and DNA fragmentation of K 562 Cells. These results suggest that As 2O 3 can induce the apoptosis of K 562 cells efficiently.
出处 《苏州医学院学报》 1999年第11期1156-1158,共3页 Acta Academiae Medicinae Suzhou
基金 苏州医学院附属一院青年骨干基金
关键词 三氧化二砷 K562细胞 细胞凋亡 白血病 CML arsenic trioxide K 562 cell apoptosis
  • 相关文献

参考文献2

共引文献37

同被引文献21

  • 1Horita M, Andreu E J, Benitor A, et al. Blockade of the Bcr-Abl kinasc activity induces apoptosis of chronic myelogenous leukemis cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-Ⅺ[J]. J Exp Med,2000, 191(6) :977-984.
  • 2Pirkins C, Kim C N, Fang G, et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukermia cells that express Bcr-Abl or overexpress MDR,MRP,Bcl-2,or Bcl-x(L)[J]. Blood, 2000, 95(3):1014-1022.
  • 3Yoshida C, Melo J V. Biology of chronic myeloid leukemia and possible therapeutic approaches:to imatinib-resistant disease[J]. Int J Hematol, 2004,79(5):420-433.
  • 4Rosee P L A, Johnson K, Dwyer O M E, et al. In vitro studies of the combination of imatinib mesyhte (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia[J]. Exp Hematol, 2002, 30(7):729-737.
  • 5Rosee P L A, Johnson K, Corbin A S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines[J]. Blood, 2004,103(1):208-215.
  • 6Nimmanapalli R, Bali P, O'Bryan E, et al. Mechanism by which arsenic trioxide downregulates Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive huaman acute leukemia cells. Blood, 2001:98:435a
  • 7La Rosee P, Johnson K, O'Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol, 2002;30: 729 - 737
  • 8Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene, 2000;19:5643 5650
  • 9Pasternak G, Hochhaus A, Schultheis B, et al. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol, 1998; 124: 643- 660
  • 10Amarante-Mendes GP, McGahon AJ, Nishioka WK, et al. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-XL. Oncogene, 1998;16:13831390

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部